Eton Pharmaceuticals, Inc. (ETON)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$58.45-2.42%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · ETON
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 58.7% |
| Our one-year growth estimate | diamond | 74.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 15.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 23 industry peers · Company calendar date is not available
ETON — COO transition
Dated 2026-08-04
Chief Operating Officer — Danka Radosavljevic: Ms. Radosavljevic was promoted to Chief Operating Officer from her previous role.
Why it matters: The earnings report will show if the company can improve its loss-making status.
Watch forEton reports smaller losses. It is moving closer to making money.
Also watch forEton reports bigger losses. There is no improvement in its finances.
Why it matters: A rebound in sector growth could benefit Eton and improve its market position.
Supportive ifSector revenue growth speeds up to 10% or more.
Worry ifSector revenue growth slows down to less than 5%.
Why it matters: Steady revenue growth shows strong demand for Eton's products. It also backs management's raised guidance.
Supportive ifIn Q3 2026, product sales go over $36 million. This shows more than 90% growth from last year.
Worry ifIn Q3 2026, product sales drop below $30 million. This shows weaker demand.
Why it matters: This would show better efficiency and more profit.
Supportive ifAdjusted EBITDA margin was at or above 30% in Q2.
Worry ifAdjusted EBITDA margin was below 30%. This shows ongoing challenges.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$235 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $452 loss on $10,000 · 4.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,617 loss on $10,000 · 36.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Continued strong sales growth is key to hitting the new revenue target of over $120 million.
Supportive ifQ2 2026 product sales growth exceeds 70% year over year.
Worry ifQ2 2026 product sales growth falls below 50% year over year.
Why it matters: More acquisitions could expand the product portfolio and support growth.
Supportive ifThere may be another acquisition or partnership. This would improve the product lineup.
Worry ifNo new M&A announcements have come out. This shows slow growth.
Why it matters: An update could indicate whether Eton is on track to exceed its revenue target of $145 million for 2026.
Watch forManagement raises revenue guidance to more than $145 million for 2026.
Also watch forManagement lowers revenue guidance to less than $145 million for 2026.
Why it matters: Positive results could lead to an important study. This would help Eton's pipeline and long-term growth.
Watch forTopline results from the ET-700 clinical study show positive results.
Also watch forTopline results from the ET-700 clinical study show no strong results.
Why it matters: Approval would help more patients use INCRELEX. This could greatly increase sales.
Supportive ifThe FDA approves the INCRELEX study.
Worry ifThe FDA denies the INCRELEX study.
Why it matters: Strong sales of IMPAVIDO could support Eton's buying plan and raise revenue.
Supportive ifSales of IMPAVIDO exceed $5 million in the first quarter after launch.
Worry ifSales of IMPAVIDO fall below $2 million in the first quarter after launch.
Why it matters: Good results could lead to more uses for KHINDIVI. This would increase its market size.
Supportive ifThe KHINDIVI study shows it works like ALKINDI SPRINKLE.
Worry ifThe KHINDIVI study does not show it works like ALKINDI SPRINKLE.
Why it matters: This margin is important for making money. It helps meet management's goals.
Supportive ifAdjusted gross margin reported above 70% in Q2 or Q3.
Worry ifAdjusted gross margin is under 70%. This shows ongoing pressure on margins.
Why it matters: Positive results could lead to a pivotal study and further pipeline growth.
Watch forThe ET-700 study shows good results compared to GALZIN.
Also watch forThe ET-700 study shows no strong results.
Why it matters: Strong revenue growth helps management raise guidance. This shows the strength of the product line.
Supportive ifQ3 2026 revenue reported above $37.6 million.
Worry ifQ3 2026 revenue falls below $30 million.
Why it matters: Approval could greatly increase the market for KHINDIVI. This would boost revenue.
Supportive ifFDA approves the expanded use of KHINDIVI by mid-2027.
Worry ifFDA denies the expanded use of KHINDIVI or delays the decision.
Why it matters: This margin shows good efficiency. It also helps the company's growth plans.
Supportive ifThe adjusted EBITDA margin is over 35% for 2026.
Worry ifThe adjusted EBITDA margin is below 30% for 2026.
Why it matters: The NDA submission for ASN-001 could lead to a new revenue stream. This product targets a large patient population with moderate infantile hemangiomas.
Supportive ifEton submits the NDA for ASN-001 by the end of 2027.
Worry ifEton delays the NDA submission for ASN-001 beyond 2027.